S. Jeson Sangaralingham, M.S, Ph.D., is a translational cardiovascular investigator who studies the mechanisms that underlie cardiorenal injury and disease, with special focus on the natriuretic peptide-particulate guanylyl cyclase-cGMP system and the bidirectional cross-talk between the heart and kidney.
Dr. Sangaralingham is specifically interested in neurohumoral and cellular signaling mechanisms that contribute to cardiorenal fibrosis and dysfunction induced by cardiovascular and chronic kidney disease, which is prevalent in the aging population. His research program employs a multidisciplinary strategy that combines human-based investigations with laboratory-based studies, including experimental models of cardiorenal injury and disease such as myocardial infarction, chronic kidney disease and heart failure; cellular and molecular biology; integrative physiology; and state-of-the-art imaging technologies.
Dr. Sangaralingham's highly collaborative scientific efforts involve investigators from the divisions of Cardiovascular Diseases, and Nephrology & Hypertension, as well as the departments of Laboratory Medicine and Pathology, and Physiology and Biomedical Engineering.
- Understanding the pathophysiology of cardiorenal injury as well as the biological processes involved in organ repair and rescue and in slowing and arresting the progression of fibrosis
- Discovering drugs and optimizing therapeutic strategies for cardiorenal protection
- Innovating biomarkers to predict, identify and prevent cardiorenal disease
Significance to patient care
Currently, there are few truly effective biomarkers and drugs that identify and target fibrosis of the heart and kidney, which are hallmarks of cardiorenal disease and injury.
Dr. Sangaralingham's clinically significant research seeks to provide a deeper understanding of biological processes that underlie the pathogenesis of cardiorenal fibrosis. He also works to translate this knowledge into novel diagnostic and therapeutic strategies to improve the quality of life for patients with cardiorenal disease or subclinical injury.
- Fellow, American Heart Association (AHA), 2015-present
- Scientist Development Grant, AHA, 2013-2017
- Career Development Award in Cardiovascular Research, St. Jude Medical Foundation, Mayo Clinic, 2014
- Jay N. Cohn New Investigator Award: Clinical/Integrative Physiology, Heart Failure Society of America, 2012